project id: TCGA-BLCA; case submitter id: TCGA-FD-A3SL; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.79; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.5; rna integrity number: 8.5; age at index: 60; days to birth: -22020; days to death: 712; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Dead; year of birth: 1951; age at diagnosis: 22020; ajcc pathologic m: M1; ajcc pathologic n: N2; ajcc pathologic stage: Stage IV; ajcc pathologic t: T4a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 683.0; icd 10 code: C67.4; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Posterior wall of bladder; synchronous malignancy: Not Reported; tissue or organ of origin: Posterior wall of bladder; tumor grade: Not Reported; year of diagnosis: 2011; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 322; days to sample procurement: 0; initial weight: 920.0; portion submitter id: TCGA-FD-A3SL-01A-21; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 25.0; percent tumor cells: 75.0; percent tumor nuclei: 75.0;